These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30046695)

  • 1. Underestimation of N-glycoPEGylated factor IX one-stage clotting activity owing to contact activator-impaired activation.
    Persson E; La Cour Christoffersen C
    Res Pract Thromb Haemost; 2017 Oct; 1(2):259-263. PubMed ID: 30046695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
    Rosén P; Rosén S; Ezban M; Persson E
    J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
    Ezban M; Hermit MB; Persson E
    Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
    Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
    J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High variability in Factor IX one-stage assay in samples spiked with nonacog beta pegol among different pairs of reagent/detection system.
    Duboscq C; Sueldo E; Rosa C; Zirpoli M; Ceresetto J; Baques A; Arias M
    Int J Lab Hematol; 2024 Feb; 46(1):128-134. PubMed ID: 37704365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reagent-specific underestimation of turoctocog alfa pegol (N8-GP) clotting activity owing to decelerated activation by thrombin.
    Persson E; Foscolo T; Hansen M
    Res Pract Thromb Haemost; 2019 Jan; 3(1):114-120. PubMed ID: 30656284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays.
    Sørensen MH; Andersen S; Ezban M
    Haemophilia; 2015 Nov; 21(6):832-6. PubMed ID: 25929807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
    Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
    J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial.
    Escuriola Ettingshausen C; Hegemann I; Simpson ML; Cuker A; Kulkarni R; Pruthi RK; Garly ML; Meldgaard RM; Persson P; Klamroth R
    Res Pract Thromb Haemost; 2019 Apr; 3(2):268-276. PubMed ID: 31011711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.
    Iorio A; MacDonald V; Caillaud A; Luckevich MD; Christoffersen P; Matino D; Keepanasseril A; Iserman E; Germini F; Bentley A; Poon MC
    Res Pract Thromb Haemost; 2023 Mar; 7(3):100106. PubMed ID: 37065846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
    Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
    Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
    J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.
    Chan AK; Alamelu J; Barnes C; Chuansumrit A; Garly ML; Meldgaard RM; Young G
    Res Pract Thromb Haemost; 2020 Oct; 4(7):1101-1113. PubMed ID: 33134776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
    Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
    Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FIX potency of rFIX-Albumin fusion protein is underestimated by one-stage methods using silica-based APTT reagents.
    Rosén S; Bryngelhed P
    Haemophilia; 2020 Mar; 26(2):340-345. PubMed ID: 32006459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency estimates for recombinant factor IX in the one-stage clotting assay are influenced by more than just the choice of activated partial thromboplastin time reagent.
    Wilmot HV; Gray E
    Haemophilia; 2018 Sep; 24(5):e363-e368. PubMed ID: 30051554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonacog beta pegol prophylaxis in children with hemophilia B: safety, efficacy, and neurodevelopmental outcomes for up to 8 years.
    Walsh KS; Mrakotsky C; Carcao M; Chan AKC; Nielsen PH; Holst H; Shapiro K
    Res Pract Thromb Haemost; 2024 Feb; 8(2):102341. PubMed ID: 38516633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
    Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
    Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, tissue distribution, excretion, and metabolite profiling of PEGylated rFIX (nonacog beta pegol, N9-GP) in rats.
    Sternebring O; Christensen JK; Bjørnsdottir I
    Eur J Pharm Sci; 2016 Sep; 92():163-72. PubMed ID: 27378188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.